Navigation Links
Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
Date:12/11/2008

squamous NSCLC patients. The importance of accurately identifying squamous cell lung cancer patients has been receiving growing attention from the medical community as data has shown that squamous patients respond differently to targeted therapies, approved or in advanced development, than non squamous patients. The difference in response can range from potential fatal bleeding to poor response."

"Given the varying outcomes of targeted therapies for NSCLC, we view every NSCLC patient, who is a candidate for targeted therapy, as a potential end-user for this test," said Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. "This groundbreaking test, with its high sensitivity and specificity, will enable doctor and patient to adjust expectations, and answer a real unmet medical need."

miRview(TM) squamous classifies non-small cell lung carcinoma samples into two histological groups: cancers of squamous histology, and non-squamous cancers. The test leverages proprietary microRNA technology developed by Rosetta Genomics, and measures the expression level of a microRNA squamous biomarker to differentiate patients that have squamous cell carcinoma of the lung from patients that have non-squamous non-small cell lung cancer.

Patients with squamous cell carcinoma of the lung have shown varying response patterns to targeted therapies, whether currently available or under development, ranging from a high incidence of severe or fatal hemoptysis (internal bleeding in the lungs) to overall poor response.

Current methods for differentiating squamous from non squamous non-small cell lung cancer lack standardization, are difficult to reproduce, and have low accuracy. Studies that reviewed the accuracy and reproducibility of histopathological classification of lung cancer found that 30%~40% of samples had been misclassified.

Rosetta Genomics will host a conference call with a simul
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
7. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
8. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
9. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
10. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- The Physician-Patient Alliance for Health & Safety ... "Surviving Your Hospital Stay: Physician-Patient Alliance for Health ... A sentence was omitted from the release. ... is a member of the National Coalition to Promote ... the National Coalition to Promote Continuous Monitoring of Patients ...
(Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Final results from,a 24-week study presented today at ... olanzapine long-acting injection (LAI),therapeutic doses showed a maintenance ... review of pooled safety data from all olanzapine ... Olanzapine LAI is an investigational formulation that ...
... 2 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the signature of ... de Lausanne (EPFL), aimed at the identification ... with pathways controlling cell fate,specification. The project, ...
Cached Medicine Technology:Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 2Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 3Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 4Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 5Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 6Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 7Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 8Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 9Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment 2
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... ... refusing travellers with symptoms similar to flu to board planes, travel insurers are treating swine ... ... AA Travel Insurance are now enquiries from travellers concerned about whether they are covered if ...
... who struggle with CPAP treatment for obstructive sleep apnea ... the upper airway, because it holds the same quality-of-life ... in new research published in the August 2009 edition ... positive airway pressure (CPAP) therapy is a highly effective ...
... Speaker Nancy Pelosi issued the following statement tonight on the vote ... Affordable Health Choices Act, the third House committee to pass the ... Education and Labor Committee approved the bill earlier this month: ... have tried as a nation to make quality, affordable health insurance ...
... for people living with AIDS and increases with increasing ... 31 in the Journal of the National Cancer ... is known to be higher among people with AIDS, ... is unclear. Anil K. Chaturvedi, Ph.D., of the ...
... , NEW YORK, July 31 BBV Vietnam ... "Company") announced today that it has signed a non-binding letter of ... Pursuant to the provisions of the Company,s Articles of Incorporation, the ... combination. If the Company is unable to complete the business combination ...
... more health and social issues years later , FRIDAY, July ... neuroblastoma face long-term health and social problems, according to a ... who had been diagnosed with neuroblastoma -- a cancer that ... comparing it with data on 3,899 siblings of children with ...
Cached Medicine News:Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 2Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 3Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 4Health News:AIDS patients face higher risk of HPV-related cancers as immunosuppression grows 2Health News:BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc. 2
... Launched in 1996, VISIPAQUE is the only isosmolar ... an osmolality equal to that of blood, VISIPAQUE ... is also the only contrast medium formulated with ... blood. In 1997, VISIPAQUE received FDA approval for ...
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
Hand surgery basic instrument set...
Castroviejo caliper...
Medicine Products: